BioStacks

Stress & Mood — Clinical Research

Evidence from published RCTs, systematic reviews, and meta-analyses.

Last reviewed: 3 March 2026

Strong Clinical Evidence

Ashwagandha (Withania somnifera)

VERY HIGH

Therapeutic dose: 300–600 mg/day standardized extract (≥5% withanolides)

2022 meta-analysis of 12 RCTs (1,002 participants) found ashwagandha significantly reduced anxiety (SMD: -1.55, p=0.005) and stress (SMD: -1.75, p=0.005).
2024 meta-analysis of 9 RCTs (558 participants) reduced PSS (MD=-4.72), HAM-A (MD=-2.19), and serum cortisol (MD=-2.58), all p<0.05.
2025 meta-analysis of 15 RCTs (873 participants) confirmed significant reductions in cortisol, PSS, and HAM-A scales.
2025 BJPsych Open systematic review confirmed benefits for anxiety, depression, sleep, and stress. Optimal forms: KSM-66 or Sensoril (most studied).
Mechanism: reduces cortisol via HPA axis modulation with additional GABAergic activity and anti-inflammatory effects. Full benefits at 6–8 weeks; some effects at 2–4 weeks.

Lavender Oil — Silexan (Lavandula angustifolia)

HIGH

Therapeutic dose: 80–160 mg/day Silexan

2023 meta-analysis of 5 RCTs (1,213 participants) found 80 mg/day significantly superior to placebo (HAMA MD: 2.93, p<0.001) after 10 weeks.
2019 network meta-analysis found 80 mg comparable to paroxetine 20 mg. At 160 mg, Silexan was superior to all comparators.
GAD trial (539 adults, 10 weeks): 160 mg achieved ≥50% HAMA reduction in 60.3% of participants vs 37.8% placebo.
18-month safety data showed favorable profile with fewer side effects than lorazepam and no dependence. Included in German anxiety guidelines.
Key limitation: nearly all trials by manufacturer in Germany; limited independent replication. Generic lavender oil is NOT equivalent to Silexan.

L-Theanine

HIGH

Therapeutic dose: 200–400 mg/day (do NOT exceed 655 mg)

2025 meta-analysis of 18 RCTs (897 participants) found improved sleep quality (SMD=0.43, p=0.03) and daytime dysfunction (SMD=0.33, p<0.001). Objective measures (actigraphy, PSG) did not improve.
2024 RCT (200 mg/day, 4 weeks) reduced stress (SDS), trait anxiety (STAI), sleep disturbance (PSQI), and improved verbal fluency.
AlphaWave single-dose RCT (200 mg) increased alpha brain waves, reduced anxiety, and lowered salivary cortisol.
Mechanism: increases alpha waves and modulates GABA, serotonin, and dopamine — producing relaxation without sedation. Acute effects same day; cumulative benefits at 2–4 weeks.

St. John's Wort (Hypericum perforatum)

VERY HIGH

Therapeutic dose: 600–1,200 mg/day standardized extract (0.3% hypericin or 2–5% hyperforin)

Cochrane Review (29 RCTs, 5,489 patients): hypericum extracts superior to placebo (RR 1.28 in larger trials) and similarly effective as SSRIs (RR 1.00). Significantly fewer dropouts due to adverse effects vs SSRIs (OR 0.53).
2017 meta-analysis (27 trials, 3,808 patients vs SSRIs): comparable response rate (RR 0.983) and remission rate (RR 1.013), with significantly lower discontinuation (OR 0.587).
WS 5570 RCT (375 patients, 6 weeks): 900 mg/day significantly superior to placebo on HAM-D in mild-moderate MDD.
Critical limitation: potent CYP3A4/P-gp inducer — significantly reduces efficacy of oral contraceptives, warfarin, cyclosporine, HIV antiretrovirals. Not safe with SSRIs (serotonin syndrome risk).

SAMe (S-Adenosylmethionine)

HIGH

Therapeutic dose: 800–1,600 mg/day enteric-coated tablets

2024 meta-analysis (23 RCTs, 2,183 patients): SAMe monotherapy significantly superior to placebo (SMD = -0.58). No significant difference from antidepressants (SMD = 0.06).
Cochrane Review: SAMe superior to placebo and equivalent to TCAs. Global effect size 17–38%.
SRI augmentation RCT (Papakostas 2010): SAMe 800 mg BID as adjunct showed significantly higher response (36.1% vs 17.6%) and remission (25.8% vs 11.7%) in SSRI non-responders.
Chemically unstable — quality/storage matters enormously. Enteric-coated tosylate or butanedisulfonate forms required. May trigger mania in bipolar patients.

Moderate Evidence

Rhodiola rosea

MODERATE

Therapeutic dose: 288–680 mg/day (3% rosavins + 1% salidroside)

2012 systematic review of 11 RCTs found 3/5 mental fatigue studies positive, 2/6 physical performance studies positive. Concluded 'evidence contradictory with methodological flaws.'
Cropley 2015 (80 mildly anxious adults, 400 mg, 14 days): significant reduction in anxiety, stress, anger, confusion, and depression.
GAD pilot (10 subjects, 340 mg, 10 weeks): 50% achieved ≥50% HAMA reduction. Promising but extremely small sample.
Key limitation: high risk of bias and no consistent outcome measures across studies. Optimal form: SHR-5 standardized extract.

Magnesium

MODERATE

Therapeutic dose: 200–400 mg/day elemental magnesium

2017 systematic review found suggestive benefit in anxiety-vulnerable samples, though evidence quality was poor.
2024 depression meta-analysis of 7 RCTs showed significant benefit (SMD: -0.919, p=0.001).
Form matters enormously: bisglycinate ~80% bioavailability vs oxide 4–10%. A 400 mg oxide product delivers only ~30–50 mg absorbed magnesium.
Mechanism: GABA-A receptor agonist + NMDA receptor antagonist; reduces cortisol. Benefits primarily in deficient populations.

Omega-3 (EPA/DHA)

MODERATE

Therapeutic dose: 1,000–2,500 mg/day EPA+DHA

2024 meta-analysis of 23 RCTs (2,189 participants): each 1g/day produced a moderate anxiety decrease (SMD: -0.70).
2021 reactivity RCT (138 adults): 2.5g/day lowered cortisol and IL-6 by 33%.
Negative finding (2017): 2.2g/day showed NO effect on PSS in chronic work stress — benefits may be limited to anxiety rather than perceived stress.
Optimal form: EPA-rich triglyceride form. Mechanism: anti-inflammatory + HPA axis modulation. Requires 8–12 weeks for full effect.

Holy Basil / Tulsi (Ocimum tenuiflorum)

MODERATE

Therapeutic dose: 250–1,200 mg/day

2022 RCT (100 adults, 250 mg/day, 8 weeks): PSS improved (p=0.003), hair cortisol lower (p=0.025), acute stress buffered (cortisol p=0.001).
OciBest RCT (150 participants, 1,200 mg/day, 6 weeks): reduced stress symptom scores (p≤0.05).
2017 systematic review of 24 studies: all favorable — described as effective adaptogen for modern stresses.
Mechanism: inhibits CRH receptor-1, reduces cortisol/amylase, enhances serotonin/dopamine. Optimal forms: Holixer or OciBest (standardized).

Saffron (Crocus sativus)

MODERATE

Therapeutic dose: 28–30 mg/day standardized extract (≥2% safranal, ≥10% crocins)

2019 meta-analysis (Nutrition Reviews) of RCTs found large effect sizes for both depression (Hedges' g=0.99) and anxiety (g=0.95) vs placebo.
2024 meta-analysis (PubMed 38913392) concluded saffron is comparable to SSRIs for depression and anxiety with significantly fewer adverse events.
2021 stress RCT (PMC7882499): saffron delayed peak salivary cortisol during Trier Social Stress Test, demonstrating direct cortisol modulation.
2025 RCT: 28 mg/day affron® improved mood and stress scores at 5 weeks in healthy adults.
Key limitation: noted publication bias in meta-analyses. Nearly all positive trials use branded extracts (affron®). Safe up to 1.5g/day with no severe adverse events reported.

B Vitamin Complex

MODERATE

Therapeutic dose: Multi-B ≥3 vitamins at RDA+

2019 meta-analysis of 16 trials (2,015 participants): significant benefit for stress (p=0.03). Depression: p=0.07 (trend). Anxiety: p=0.71 (no effect).
5 of 8 at-risk population studies found significant benefit — effects more pronounced in stressed or nutritionally at-risk individuals.
Key distinction: B vitamins reduce perceived stress but do NOT reduce anxiety or depression — important for scoring specificity.
Optimal form: methylated (methylfolate, methylcobalamin, P-5-P). Requires 4+ weeks for effect. Often confounded by combination products in studies.

Phosphatidylserine (PS)

MODERATE

Therapeutic dose: 300–800 mg/day (400 mg minimum effective dose)

2014 RCT (75 men): 400 mg normalized cortisol response (p=0.043). Critically, 200 mg had NO effect — dose threshold is real.
2008 exercise RCT: 600 mg/day reduced cortisol AUC by 35% (p<0.01) and increased testosterone by 37% (p=0.02).
Consistent cortisol-blunting across studies, but 400 mg minimum dose means many products are underdosed at 100–200 mg.
Optimal form: soy-derived PS, often combined with phosphatidic acid or omega-3. Mechanism: blunts HPA axis, reduces cortisol and ACTH.

Curcumin (from Turmeric)

MODERATE-HIGH

Therapeutic dose: 500–1,500 mg/day curcuminoids (bioavailability-enhanced form)

2017 meta-analysis (6 RCTs, 377 patients): curcumin significantly reduced HAM-D scores vs placebo (SMD = -0.344). No adverse events.
2025 meta-analysis (15 RCTs, 1,123 patients): nanocurcumin showed strong effects (SMD = -1.30) while standard curcumin did not reach significance (SMD = -0.40).
Lopresti RCT (56 MDD patients): 1,000 mg/day significantly improved IDS-SR30 from week 4 and reduced IL-1β, TNF-α, and cortisol.
Standard curcumin has <1% bioavailability. Nanocurcumin/phytosome forms (Meriva, BCM-95) are essential for efficacy.

Vitamin D

MODERATE

Therapeutic dose: 2,000–4,000 IU/day D3 (cholecalciferol)

2024 dose-response meta-analysis (31 RCTs, 24,189 participants): each 1,000 IU/day D3 reduced depressive symptoms (SMD: -0.32). Effect more pronounced in those with depressive symptoms (SMD: -0.57).
2023 meta-analysis (41 RCTs, 53,235 participants): moderate treatment effect (Hedges' g = -0.317). Effective in both MDD and subclinical depression.
Short-term supplementation (≤8 weeks) produced stronger effects than longer regimens. Trials >52 weeks showed NO significant effect.
CANMAT guidelines do NOT recommend vitamin D as adjunct for MDD. Effects may be limited to deficient populations.

L-Methylfolate (5-MTHF)

MODERATE

Therapeutic dose: 15 mg/day L-methylfolate (lower doses not consistently effective)

2021 meta-analysis (6 RCTs, 584 participants): adjunctive folate with SSRI/SNRI significantly improved HAM-D scores (MD: -2.16), response rate (RR: 1.36), and remission rate (RR: 1.39).
Papakostas parallel-sequential RCTs: L-methylfolate 15 mg/day (but NOT 7.5 mg) significantly superior to placebo as SSRI augmentation. NNT ≈ 6.
WFSBP/CANMAT guidelines: L-methylfolate 15 mg/day provisionally recommended as adjunctive treatment for MDD. Folic acid NOT recommended.
Most supplements contain 400–1,000 mcg folic acid — a different compound that's 15–37x below effective dose. Form distinction (L-methylfolate vs folic acid) is critical.

Weak / No Evidence

Lemon Balm (Melissa officinalis)

LOW-MODERATE

Therapeutic dose: 300–3,000 mg/day

2021 meta-analysis found significant anxiety reduction (SMD: -0.98, p=0.003) and depression reduction (SMD: -0.47, p=0.0005), but with high heterogeneity.
Acute RCT (600 mg single dose) ameliorated negative mood and increased calmness.
2023 phytosome RCT (400 mg/day, 3 weeks): phospholipid extract improved anxiety, stress, and wellbeing (all p<0.001).
Key limitation: dosing varies 10x across studies (300–3,000 mg). Optimal forms: Cyracos or phospholipid-based (Relissa).

Passionflower (Passiflora incarnata)

LOW-MODERATE

Therapeutic dose: 200–1,600 mg/day

2020 review of 9 RCTs: majority reported reduced anxiety with no adverse effects.
GAD trial (36 patients): as effective as oxazepam 30 mg/day with less cognitive impairment.
2024 RCT (65 participants, 30 days): reduced PSS and improved quality of life and insomnia scores.
Successfully used in benzodiazepine tapering at 200–600 mg/day (approved in Italy as Tractana). Key limitation: mostly 1–30 day durations with small samples.

Relora (Magnolia + Phellodendron)

LOW

Therapeutic dose: 250 mg 2–3x/day (500–750 mg/day total)

Talbott 2013 (63 adults, 42 days, 750 mg/day): reduced salivary cortisol by 18% (p<0.05) and improved POMS vigor and fatigue subscales. Manufacturer-funded.
Kalman 2008 (56 adults, 4 weeks, 500 mg/day): NO significant cortisol reduction. Reduced weight gain associated with stress eating. Manufacturer-funded.
Conflicting cortisol results across the two available RCTs — one positive, one null. Both had small samples and industry funding.
Mechanism: honokiol (magnolia) is a GABAergic anxiolytic; berberine (phellodendron) modulates cortisol. GABAergic mechanism is well-characterized but clinical translation is limited.

GABA (Gamma-Aminobutyric Acid)

LOW

Therapeutic dose: 100–300 mg/day

2020 systematic review of 14 placebo-controlled trials found mixed results for oral GABA on stress and sleep, with high methodological variability.
GABA/5-HTP combination study: reduced sleep onset (32→19 min, p=0.01) and increased duration (5→6.8 hrs, p=0.01).
Fundamental question unresolved: whether supplemental GABA crosses the blood-brain barrier is debated. May act via the enteric nervous system (gut-brain axis).
PharmaGABA (fermented, natural L-form) may have better efficacy than synthetic GABA. Acute effects within 30–60 minutes.

Probiotics / Psychobiotics

LOW-MODERATE

Therapeutic dose: Strain-specific; 1–10B CFU/day

2024 meta-analysis of 23 RCTs (1,401 patients) found moderate anxiety reduction (SMD: -0.59) in clinical populations.
L. plantarum DR7 RCT (111 adults, 12 weeks): reduced anxiety (p=0.001), stress (p=0.024), and lowered cortisol.
Inconsistencies: L. rhamnosus failed to prevent cortisol elevation. B. longum at 16 weeks showed no effect.
2024 review concluded 'not yet strong enough evidence to support inclusion in treatment guidelines.' Highly strain-dependent with many null results.

Lactium (Alpha-S1 Casein Hydrolysate)

LOW

Therapeutic dose: 150–300 mg/day

Kim 2007 DB-RCT (63 women, 150 mg/day, 30 days, crossover): reduced stress symptoms across digestive (p<0.01), cardiovascular (p<0.05), intellectual (p<0.01), emotional (p<0.05), and social (p<0.05) domains.
Messaoudi 2005 DB-RCT (healthy volunteers, 200 mg acute ×3 doses): significant cortisol reduction under combined stress tests (p<0.05) and lower blood pressure changes vs placebo.
CERTAIN 2022 (100 acne patients, 150 mg/day, 12 weeks): cortisol −4.75 µg/dL (p<0.001), PSS and HAM-A improved (p<0.001). However, open-label design substantially weakens findings.
Mechanism: contains alpha-casozepine, a decapeptide from bovine alpha-s1 casein that binds GABA-A receptors with benzodiazepine-like anxiolytic action without dependence risk. No meta-analysis exists; most studies involve manufacturer Ingredia.

Zembrin (Sceletium tortuosum)

LOW

Therapeutic dose: 8–25 mg/day

2023 meta-analysis of 4 studies (117 participants) concluded 'no clinical difference' between Sceletium tortuosum and placebo for anxiety. Stated it is 'not possible to guarantee Sceletium tortuosum affects anxiety.'
Reay 2020 RCT (20 healthy volunteers, single 25 mg dose): Study 1 null; Study 2 showed lower pre-stress anxiety. Authors called it 'first tentative behavioral evidence.'
Terburg 2013 fMRI (16 participants, single 25 mg dose): attenuated amygdala reactivity to fearful faces — mechanistic/neuroimaging only, not clinical stress outcomes.
Mechanism: dual PDE4 inhibitor + 5-HT reuptake inhibitor — pharmacology is well-characterized. No chronic supplementation RCTs measuring stress/anxiety as primary endpoints. No cortisol data in any study.

5-HTP (5-Hydroxytryptophan)

LOW

Therapeutic dose: 150–300 mg/day

Direct serotonin precursor with strong theoretical rationale, but modern clinical evidence is remarkably thin. 2012 Cochrane review found insufficient evidence.
One of the most popular mood supplements, yet its evidence base is among the weakest. Should NOT be combined with SSRIs/SNRIs (serotonin syndrome risk).

Zinc

LOW-MODERATE

Therapeutic dose: 25–50 mg/day elemental zinc

Multiple meta-analyses show lower serum zinc in depressed individuals. 2013 meta-analysis of adjunctive zinc (25 mg/day) with antidepressants showed significant improvement.
Evidence for standalone mood benefit is limited. Primarily an adjunctive cofactor role.